Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01239381 · ClinicalTrials.gov registry record · NA
Individualized Stereotactic Body Radiotherapy of Liver Metastases
A NA study of Solid Tumor and Liver Metastases, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 2
- Study locations
NCT01239381: Completed NA study of Solid Tumor and Liver Metastases, sponsored by Massachusetts General Hospital.
NCT01239381 is a NA study of Solid Tumor and Liver Metastases that has completed, run by Massachusetts General Hospital. The registered enrollment target is 92 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01239381, a NA study of Solid Tumor and Liver Metastases, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 2
- Study locations
Study Summary
Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this research study is to determine if SBRT with protons will prevent tumor growth and reduce the treatment side effects for liver metastases.
Primary Outcome
The percentage of participants with local control at primary tumor site at one year. Local is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST). Local control is defined as achieving either Complete response (CR), Partial Response (PR), or Stable Disease (SD). * (CR): Disappearance of entire lesion, with no additional evidence of disease. * (PR): At least a 30% decrease in the (sum of) the longest diameter (LD) of the primary lesion, taken as reference the baseline sum LD. *
Conditions Studied
Interventions
- RADIATION Stereotactic body radiotherapy-proton
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institue - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-10-05 |
| Est. Completion | 2017-09-01 |
| Phase | NA |
What the finished NCT01239381 record still lists
NCT01239381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic body radiotherapy-proton is the first listed.
NCT01239381 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01239381 about?
NCT01239381 is a clinical study titled "Individualized Stereotactic Body Radiotherapy of Liver Metastases". Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this resea...
What is the current status of trial NCT01239381?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2010-10-05. Estimated completion is 2017-09-01.
What conditions does trial NCT01239381 study?
This clinical trial studies the following conditions: Solid Tumor, Liver Metastases.
What interventions are being tested in trial NCT01239381?
The interventions under investigation include: Stereotactic body radiotherapy-proton (RADIATION).
Who is sponsoring clinical trial NCT01239381?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01239381 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01239381's enrollment target sits among peer trials
92 92nd of 196 higher than 105 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
RECRUITING · NA
-
Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
RECRUITING · NA
-
Psychotherapy Intervention for Latinos With Adv Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI